Meeting
2024 ASCO Annual Meeting
Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): An open-label, single-arm, phase 2 study.
Authors
Zhigong Wei
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
Zhigong Wei , Huijiao Chen , Lei Cai , Fei Chen , Jun Liu , Xingchen Peng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT05517330
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 6073)
DOI
10.1200/JCO.2024.42.16_suppl.6073
Abstract #
6073
Poster Bd #
389
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.
First Author: Hsiang-fong Kao
First Author: Christoph Mancao
Poster
2024 ASCO Annual Meeting
Neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.
First Author: Lin Gui
Poster
2024 ASCO Annual Meeting
Prediction for major pathologic response after neoadjuvant tislelizumab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma by RNA sequencing: A single-arm, phase II trial.
First Author: Wei Guo